Loading data for IMMP — first visit, this takes a few seconds.
Immutep Limited (IMMP)
NasdaqGM: IMMP
· 即時價格 · USD
0.38
+0.01 (2.70%)
收盤價: Sep 02, 2026, 5:55 PM
股價、關鍵數字和最新消息,都在這一頁。
Immutep Limited(IMMP)股價、分析與資料
無可用資料
| 買價 | 0.29 |
| 市值 | 55.4M |
| 營收 (ttm) | 19.9M |
| 淨利(ttm) | -79.3M |
| 2.19 | |
| -0.39 | |
| n/a | |
| -1.45 | |
| P/B (ttm) | 0.78 |
| P/S (ttm) | 2.78 |
| 財報日期 | Feb 23, 2027 |
| 賣價 | 0.5 |
| 成交量 | 115,868 |
| 20 日平均成交量 | 290,241 |
| 開盤價 | 0.38 |
| 前收盤價 | 0.37 |
| 當日區間 | 0.37 - 0.39 |
| 52 週範圍 | 0.29 - 3.53 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 IMMP
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clin...
完整的公司簡介財報驚奇
Immutep 已於 Invalid Date 公布季度財報:
- 營收為 n/a 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 低於預期 , 年增 NaN% 成長.